Staphylococcal vaccines: a realistic dream.
Staphylococcus aureus, especially multidrug resistant strains, continues to be a leading cause of serious nosocomial infections. In spite of the debate among investigators in the field, the discovery of serologically distinct capsular polysaccharides on the surface of clinical isolates has renewed the prospects for development of vaccines and passive protective immunity against S. aureus infections. Capsular polysaccharide conjugate vaccines have now been produced and proven to be safe and immunogenic in both healthy and in a significant percentage of immunocompromised patients. Antibodies generated in humans against these vaccines have been shown to mediate type-specific opsonophagocytosis, and to protect animals against lethal challenge with the appropriate S. aureus isolate.
Fattom
A I
AI
Univax Biologics Inc., Rockville, MD 20852, USA.
Naso
R
R
D000818:Animals; D016667:Bacterial Capsules / Q000276:immunology; D004195:Disease Models, Animal; D006801:Humans; D016867:Immunocompromised Host; D007231:Infant, Newborn; D051379:Mice; D008807:Mice, Inbred BALB C; D013209:Staphylococcal Vaccines / Q000276:immunology; D013211:Staphylococcus aureus / Q000276:immunology*; D018074:Vaccines, Conjugate
D013209:Staphylococcal Vaccines; D018074:Vaccines, Conjugate